text.skipToContent text.skipToNavigation

Lonza Bioscience blog

Lonza at CRISPRMED26 conference in Copenhagen, Denmark

Lonza returned to Copenhagen this year for CRISPRMED26 - marking our third time as a sponsor at Europe’s only conference dedicated entirely to CRISPR/Cas technologies.

With over 400 participants from across the globe, the event brought together a vibrant mix of researchers, innovators, and industry experts. From cutting-edge talks to hands-on workshops and lively poster sessions, the focus was clear: Pushing the boundaries of genome editing.

Participants could gain the latest insights on 

  • New CRISPR tools and functional genomics platforms,
  • Advances in delivery strategies,
  • Clinical progress towards therapies,
  • AI-driven therapeutic development.

During the event we hosted a Lonza booth featuring our Nucleofector® Platform, supporting any CRISPR applications from small scale to screening and large-scale therapeutic applications. 
 

Sharing newest R&D data

In addition, Stefanie Muethel (Team Lead, R&D Lonza Cologne) presented the latest results using the 4D-Nucleofector® LV Unit PRO for the large scale transfection of T cells, NK cells, and CD34+ cells, both in a talk and during the poster session. She showed data for electroporation of genome editing cargos including CRISPR knock-outs, CRISPR knock-ins and transposon-transposase based integrations. 
 

Coffee, Conversations - and Community

Not everything happened in lecture halls. A crowd favorite was our sponsored coffee tuk-tuk, serving fresh coffee and creating a natural hub for informal exchange. Not only we, but also many other genome engineers enjoyed a freshly brewed coffee.

On Wednesday, we hosted a seminar featuring a short presentation on our  Nucleofector® Technology including brand new genome editing data, followed by an open panel discussion. To conclude, we held an interactive pub quiz – four lucky winners received a Nucleofector® Kit for free to support their next CRISPR experiments.

Curious to learn more about how Nucleofector® Technology supports genome editing workflows – from early discovery to large-scale applications?

Check out our dedicated page on genome editing: Efficient Genome Editing using Nucleofector® Technology



Written by
 

Camilla
Scientific Support Specialist 

Building advanced cell models for toxicity testing

In vivo–relevant cell models are key to successful drug development. Discover Lonza’s advanced cell models designed to accelerate your research.

The challenge of cellular delivery

Comparing popular cellular delivery vehicles, and when to use exosomes as the mechanism of choice. 

Automating transformation in non-model bacteria

A case study on optimizing electroporation workflows for non-model bacteria.

Why media matters in gene therapy

The impact of media on AAV production in HEK 293 cells.

Lonza Cologne at B2Run charity run

Living our values, making an impact at this annual charity event since 2012

How to find the right target

Target identification using the 4D-Nucleofector® System in IPFs.

What is high-throuput screening?

Providing a foundational basis for understanding screening and its purpose as well as the steps involved.

Lonza's crew: From the lab to the track

In September, 39 employees of Lonza Cologne registered, running for health, charity, and sustainability and a free T-shirt—rain or shine.

CAR therapy for newbies:
Traps and pitfalls

The new trend of 'personalized medicine' requires careful preparation to achieve desired outcomes.


Mycoplasma contamination impairs transfection efficiency

Learn how mycoplasma affects your transfection and how you can obtain reliability, reproducibility, and consistency results.

Unlocking new possibilities with cryopreserved PBMCs

Insights in how cryopreservation impacts the viability and functionality of PBMCs.

Speeding up the PyroCell® MAT Testing

PyroCell® Monocyte Activation Test Rapid kits are reducing the total assay time to as little as 2 hours.

CRISPR screen of SAECs with 384-well Nucleofector® System

Find out more about the detailed automated arrayed CRISPR screening workflow for SAECs.

Lonza joins the B2Run in Cologne: Running for a cause

In a world where corporate culture is evolving, Lonza's engagement in events like the B2Run showcases their dedication to a healthier, more connected, and greener future.

Review on the CRISPR virtual event 2022

Read our short summary of the two sessions and a roundtable with interesting insights from our CRISPR experts.

How to create your own quote on our website

Find out how to generate and download a quote yourself on our Lonza Bioscience website.

CRISPR off-target effects

How to quickly detect off-targets when performing experiments with CRISPR/Cas9 technology.

Senescent zombie in primary cell culture

These zombie cells are known to reduce proliferation capacity and gradually decay culture.

The basics of clinical trials

Learn more about the clinical trials: What are they exactly? What types of trials are there? How many phases are there? What happens in each phase?

Endotoxin detection certificates of analysis

A General Guide